International Session（Symposium）3(JSGE・JGES・JSGS・JSGCS)
Thu. November 5th   14:00 - 17:00   Room 11: Portopia Hotel South Wing Topaz
IS-S3-5_G
 Recent advance of biomarkers for monitoring disease activity of IBD
Hideki Iijima
Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine
Recent development of medications enabled better improvement of inflammatory bowel disease (IBD) including establishment of mucosal healing. Although ileocolonoscopy is the current golden standard to monitor disease activity of IBD, it is invasive and expensive and is difficult for the frequent application. Therefore, biomarkers to monitor disease activity of IBD need to be developed.
C-reactive protein (CRP) is a widely-used serum biomarker and it correlates well with clinical activity of IBD. However, CRP is often not elevated in patients with mildly active patients with ulcerative colitis (UC) or Crohn’s disease (CD) with small bowel involvement. Fecal calprotectin (fCal) is a sensitive biomarker to monitor disease activity of UC. Although negative fCal relates to remissive disease status of UC, the correlation of fCal levels and disease activity is relatively poor in active patients. In addition, collecting fecal samples is inconvenient and it takes time until obtaining the results. We recently reported that serum leucine-rich alpha-2 glycoprotein (LRG) as a novel biomarker to monitor disease activity of IBD. Our retrospective and prospective study revealed that LRG is a sensitive biomarker which correlates with the clinical and endoscopic disease activity in both UC and CD. Disease monitoring with these biomarkers will expected to contribute to obtain better outcome for IBD.
Index Term 1: biomarker
Index Term 2: LRG
Page Top